menu
    • menu
    [{"orgOrder":0,"company":"EydisBio","sponsor":"National Institute of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"EYD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EydisBio \/ National Institute of Health","highestDevelopmentStatusID":"14","companyTruncated":"EydisBio \/ National Institute of Health"},{"orgOrder":0,"company":"EydisBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"EYD-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EydisBio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"EydisBio \/ Not Applicable"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"EydisBio \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"EydisBio \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by EydisBio

    Menu

    EydisBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EydisBio Wins $0.5M Grant for Alzheimer’s TAK1 Inhibitor Program

                            Details : The grant will support EydisBio's pioneering research into new therapeutic approaches for Alzheimer's disease, focusing on the inhibition of TGFβ-activated protein kinase 1 (TAK1).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor in Systemic Sclerosis

                            Details : EYD-001 is a highly selective and potent, orally bioavailable TAK1 inhibitor, which is being evaluated for the treatment of patients with systemic sclerosis.

                            Brand Name : HS-276

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2024

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            EydisBio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institute of Health

                            Deal Size : $2.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EydisBio Awarded $2.6M Grant to Advance TAK1 Inhibitor Program for Systemic Sclerosis

                            Details : The grant will be used to further support EydisBio's ongoing research into the efficacy of EYD-001, a TAK1 inhibitor in animal models of systemic sclerosis.

                            Brand Name : EYD-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Health

                            Deal Size : $2.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth